v3.26.1
Consolidated Statements of Stockholders' Equity and Mezzanine Equity - USD ($)
Common Stock [Member]
Preferred Stock [Member]
Series A Preferred Stock [Member]
Preferred Stock [Member]
Series B Preferred Stock [Member]
Preferred Stock [Member]
Series C-1 Preferred Stock [Member]
Preferred Stock [Member]
Series C-2 Preferred Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Series C-1 Preferred Stock [Member]
Series C-2 Preferred Stock [Member]
Total
Treasury Stock, Preferred [Member]
Series C-1 Preferred Stock [Member]
Treasury Stock, Preferred [Member]
Series C-2 Preferred Stock [Member]
Balance at Dec. 31, 2023 $ 1 $ 6,000,000 $ 52,710,969 $ (57,818,145)     $ 892,825  
Balances, shares at Dec. 31, 2023 8,655 1,200,000                
Mezzanine equity, shares at Dec. 31, 2023                      
Mezzanine equity, value at Dec. 31, 2023                      
Preferred stock redemption, value   153     153  
Common stock issued to service providers   275,753     275,753  
Common stock issued to service providers, shares 1,006                      
Stock issued for cash   165,131     165,131  
Stock issued for cash, shares 904                      
Preferred stock issued $ 1,643,904       1,643,904  
Preferred stock issued, shares   328,780                    
Stock options issued to directors and employees   342,728     342,728  
Warrants issued with notes payable   188,755     188,755  
Convertible note modification/extinguishment   40,491     40,491  
Debt conversion   387,033     387,033  
Debt conversion, shares 1,044                      
Warrants issued   971,012     971,012  
Warrant exercise   900,611     900,611  
Warrant exercise, shares 2,803                      
Consideration for NAYA Therapeutics, value $ (1,643,904) $ (6,000,000) $ 30,375,000   (6,696,181)     16,034,915   $ 7,457,000
Consideration for NAYA Therapeutics, shares 1,140 (328,780) (1,200,000) 30,375               8,576
NAYA debt conversion        
Deemed dividend   250,635 (250,635)      
Returned shares        
Returned shares, shares (1)                      
Net loss attributable to INVO Fertility, Inc. (9,258,953)     (9,258,953)  
Balance at Dec. 31, 2024 $ 1 $ 30,375,000 49,537,090 (67,327,733)     12,584,358   $ 7,457,000
Balances, shares at Dec. 31, 2024 15,551 30,375              
Mezzanine equity, shares at Dec. 31, 2024               30,375 8,576     8,576
Mezzanine equity, value at Dec. 31, 2024                       $ 7,457,000
Mezzanine equity, value at Dec. 31, 2024                   7,457,000   7,457,000
Reclassification of Series C-2 Preferred stock from mezzanine equity, value       $ 30,375,000         30,375,000    
Reclassification of Series C-2 Preferred stock from mezzanine equity, shares       30,375              
Balance at Mar. 31, 2025                   (27,039,635)    
Mezzanine equity, shares at Mar. 31, 2025               30,375        
Mezzanine equity, value at Mar. 31, 2025               $ 30,375,000   34,353,922    
Balance at Dec. 31, 2024 $ 1 $ 30,375,000 49,537,090 (67,327,733)     12,584,358   $ 7,457,000
Balances, shares at Dec. 31, 2024 15,551 30,375              
Mezzanine equity, shares at Dec. 31, 2024               30,375 8,576     8,576
Mezzanine equity, value at Dec. 31, 2024                   7,457,000   $ 7,457,000
Net loss attributable to INVO Fertility, Inc.                   (21,022,555)    
Balance at Jun. 30, 2025                   (6,990,122)    
Mezzanine equity, shares at Jun. 30, 2025                 10,719      
Mezzanine equity, value at Jun. 30, 2025                   10,121,922    
Balance at Dec. 31, 2024 $ 1 $ 30,375,000 49,537,090 (67,327,733)     12,584,358   $ 7,457,000
Balances, shares at Dec. 31, 2024 15,551 30,375              
Mezzanine equity, shares at Dec. 31, 2024               30,375 8,576     8,576
Mezzanine equity, value at Dec. 31, 2024                   7,457,000   $ 7,457,000
Net loss attributable to INVO Fertility, Inc.                   (24,418,153)    
Balance at Sep. 30, 2025                   5,817,688    
Balance at Dec. 31, 2024 $ 1 $ 30,375,000 49,537,090 (67,327,733)     12,584,358   $ 7,457,000
Balances, shares at Dec. 31, 2024 15,551 30,375              
Mezzanine equity, shares at Dec. 31, 2024               30,375 8,576     8,576
Mezzanine equity, value at Dec. 31, 2024                   7,457,000   $ 7,457,000
Preferred stock redemption, value   (521,922)     (521,922)   (3,478,078)
Common stock issued to service providers $ 6 $ 1,097,000 216,936     1,313,942  
Common stock issued to service providers, shares 65,617       1,097              
Stock options issued to directors and employees 178,729     178,729  
Debt conversion $ 10 $ 4,759,000 989,951     5,748,961  
Debt conversion, shares 96,590       4,759              
Warrant exercise $ 4 1,109,625     1,109,629  
Warrant exercise, shares 40,910                      
Net loss attributable to INVO Fertility, Inc. (23,323,054)     (23,323,054)  
Reclassification of Series C-2 Preferred stock from mezzanine equity, value $ 3,978,922     3,978,922   $ (3,978,922)
Reclassification of Series C-2 Preferred stock from mezzanine equity, shares         4,576             (4,576)
Preferred stock redemption, shares                       (4,000)
Proceeds from the sale of common stock, net of fees and expenses $ 25 12,355,582     12,355,607  
Proceeds from the sale of common stock, net of fees and expenses, shares 244,069                      
Warrant exercise - cashless      
Warrant exercise - cashless, shares 1,960                      
Warrant exercise - pre-funded $ 4 971     975  
Warrant exercise - prefunded, shares 38,210                      
C-1 to C-2 exchange $ (2,025,000) $ 3,213,000 (837,821)     350,179  
C-1 to C-2 exchange, shares       (2,025) 3,213              
Divesture of NAYA $ (28,350,000) 24,368,110     (3,981,890)  
Divesture of NAYA, shares       (28,350)                
Proceeds from the sale of preferred stock $ 2,850,000     2,850,000  
Proceeds from the sale of preferred stock, shares         2,850              
Dividends on preferred stock $ 244,437 (718,616)     (474,179)  
Dividends on preferred stock, shares         245              
C-2 to common stock exchange $ 189 $ (13,736,000) 13,735,811      
C-2 to common stock exchange, shares 1,883,714       (13,736)              
Fair value of warrants issued with notes payable 167,863     167,863  
Changes in fair value of derivatives (5,113,899)     (5,113,899)    
Rounding for reverse split      
Rounding for reverse split, shares 205                      
Balance at Dec. 31, 2025 $ 239 $ 2,406,359 96,187,026 (91,369,403)     7,224,221  
Balances, shares at Dec. 31, 2025 2,386,826 3,004              
Mezzanine equity, shares at Dec. 31, 2025                 3,004    
Mezzanine equity, value at Dec. 31, 2025                    
Balance at Mar. 31, 2025                   (27,039,635)    
Mezzanine equity, shares at Mar. 31, 2025               30,375        
Mezzanine equity, value at Mar. 31, 2025               $ 30,375,000   34,353,922    
Debt conversion       (178,675)     (178,666)    
Debt conversion, shares                      
Warrant exercise       (736,896)     (736,896)    
Net loss attributable to INVO Fertility, Inc.       (3,618,969)     (3,618,969)    
Reclassification of Series C-2 Preferred stock from mezzanine equity, shares                   4,576
C-1 to C-2 exchange       (837,821)     (837,821)    
C-1 to C-2 exchange, shares                    
Divesture of NAYA       24,368,110     24,368,110    
Divesture of NAYA, shares                      
Proceeds from the sale of preferred stock              
Proceeds from the sale of preferred stock, shares                      
Balance at Jun. 30, 2025                   (6,990,122)    
Mezzanine equity, shares at Jun. 30, 2025                 10,719      
Mezzanine equity, value at Jun. 30, 2025                   10,121,922    
Debt conversion       $ 2,959,000 791,641     3,750,709    
Debt conversion, shares         2,959              
Net loss attributable to INVO Fertility, Inc.       (3,395,598)     (3,395,598)    
Reclassification of Series C-2 Preferred stock from mezzanine equity, shares         10,719           (10,719)
Fair value of warrants issued with notes payable       $ 167,863     167,863    
Balance at Sep. 30, 2025                   $ 5,817,688